Morganti et al. suggested that the soluble form of fractalkine triggered CX3CR1 internalisation and provided an anti-inflammatory and neuroprotective function in a mouse model of Parkinson’s disease (Morganti et al. 2012). This evidence concerns the gene CX3CR1 and Parkinson disease.